Related coverage linked through entity extraction aliases.
Apr 20, 2026
Galux completed a $29 million Series B financing and entered an MOU with OliX Pharmaceuticals to jointly develop a next-generation AI-based siRNA delivery platform. The funding will support GaluxDesign, R&D expansion and preclinical validation.
Mar 23, 2026
Monash University and Ono Pharmaceutical have signed two licence agreements for the development of anti-GPCR antibodies targeting autoimmune and inflammatory diseases. The agreements result from Ono exercising options on research collaborations announced in 2023. The partnership combines Monash's research excellence with Ono's drug development capabilities to address unmet medical needs.
Feb 18, 2026
Barcelona-based Pharmacelera closed a €6 million funding round led by Heran Partners to establish a U.S. presence and expand its quantum mechanics and AI-powered drug discovery platform.
Feb 14, 2026
Three new computational approaches enhance molecular property prediction and drug design through advanced neural networks, multimodal learning, and thermodynamic analysis of receptor-ligand interactions.
Feb 13, 2026
Artificial intelligence is increasingly used to analyze Alzheimer's datasets and inform drug discovery, while researchers identify promising new drug targets including the IDOL enzyme and somatostatin receptors that could lead to more affordable treatments.
